Browse by Person

Export as [feed] Atom [feed] RSS
Group by: Item Type | No Grouping
Number of items: 5.

Article

San-Miguel, JF, Avet-Loiseau, H, Paiva, B et al. (24 more authors) (2021) Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood. ISSN 0006-4971

Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793

Proceedings Paper

Burger, J, Tedeschi, A, Barr, PM et al. (32 more authors) (2016) International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: Oncology Research and Treatment. Annual conference of the German, Austrian and Swiss Societies for Haematology and Medical Oncology, 14-18 Oct 2016, Leipzig, Germany. Karger Publishers , p. 6.

This list was generated on Sun Dec 19 00:08:33 2021 GMT.